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Abstract
Androgeneticalopecia (AGA) isahighlyheritableconditionandthemostcommonformofhair loss inhumans.Susceptibility locihave
beendescribedontheXchromosomeandchromosome20,but these lociexplainaminorityof itsheritablevariance.Weconducteda
large-scalemeta-analysis of seven genome-wide association studies for early-onset AGA in 12,806 individuals of European ancestry.
While replicating the two AGA loci on the X chromosome and chromosome 20, six novel susceptibility loci reached genome-wide
significance (p=2.6261029–1.01610212). Unexpectedly, we identified a risk allele at 17q21.31 that was recently associated with
Parkinson’s disease (PD) at a genome-wide significant level. We then tested the association between early-onset AGA and the risk of
PD in a cross-sectional analysis of 568 PD cases and 7,664 controls. Early-onset AGA cases had significantly increased odds of
subsequent PD (OR=1.28, 95% confidence interval: 1.06–1.55, p=8.961023). Further, the AGA susceptibility alleles at the 17q21.31
locus are on theH1haplotype,which is under negative selection in Europeans andhas been linked todecreased fertility. Combining
the riskallelesof sixnovel and twoestablishedsusceptibility loci,wecreatedagenotype risk scoreand tested its associationwithAGA
in an additional sample. Individuals in the highest risk quartile of a genotype score had an approximately six-fold increased risk of
early-onset AGA [odds ratio (OR)= 5.78, p=1.4610288]. Our results highlight unexpected associations between early-onset AGA,
Parkinson’s disease, and decreased fertility, providing important insights into the pathophysiology of these conditions.
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Introduction
A main advantage of genome-wide association (GWA) studies is
that their hypothesis-free scan of the genome for genes associated
with common disease enables identification of novel associations
between different diseases and pathways. For example, a
pioneering GWA study demonstrated that susceptibility alleles
for age-related macular degeneration were found in the comple-
ment pathway [1], giving rise to novel insights into the etiology
and treatment of this condition [2].
Through previous GWA studies, we have identified genetic
determinants of androgenetic alopecia (AGA, male-pattern
baldness) that highlight the importance of the androgen pathway
in this condition [3,4]. However, these studies did not identify
readily apparent novel pathways that link AGA to other
conditions.
AGA is the most common form of hair loss in humans, affecting
80% of men by age 80 [5]. Its etiologic factors are androgen
dependency and genetic predisposition [5]. While largely a
cosmetic condition, the mechanisms influencing its etiology may
also impact upon important medical conditions such as coronary
heart disease, metabolic syndrome, and prostate cancer [6,7].
Prostate cancer is the most frequently diagnosed cancer and
ranks second as a cancer killer among men in the United States
[8]. Androgens play a key role in stimulation of normal prostate
growth and are essential in prostate cancer initiation and
progression [9]. The main genetic determinant of AGA is the
androgen receptor (AR) [3,4] and prostate cancer susceptibility loci
identified through recent GWA studies overlap with androgen
receptor binding sites [10,11] demonstrating a shared etiologic
factor in these two conditions. However, while evidence suggests
that AGA and prostate cancer are strongly influenced by androgen
sensitivity [12,13], attempts to examine the relationship between
AGA and prostate cancer through case-control studies have
yielded inconsistent results [7] [14–18].
Since previous GWA studies for AGA explained only 13.7% of
the variance in this condition [3] we aimed to identify novel
determinants of AGA and test their association with common
diseases, by undertaking a large-scale meta-analysis of GWA
studies involving 12,806 Europeans from seven cohorts included in
the Meta-Analysis for Androgenetic Alopecia Novel Determinants
(MAAN) consortium.
Results/Discussion
The current analysis comprised 3,891 cases and 8,915 controls
of European ancestry from seven independent studies: Bonn,
CoLaus, TwinsUK, Nijmegen Biomedical, 23andMe, Icelandic,
and an Australian population based twin study (Table 1). Briefly,
we used an extreme discordant case-control design to contrast
individuals with early-onset AGA to older individuals without
alopecia as assessed by questionnaire, clinical visit or photographs
evaluated by a dermatologist, where available. Genome-wide
genotyping, using standard platforms, and imputation using the
CEU panel of Phase II HapMap were performed. After the quality
control criteria were applied, 2,391,230 SNPs remained for
genotype-phenotype association analysis.
The sample size of the current meta-analysis (n = 12,806) was
more than fourfold that of the earlier GWA studies of AGA [3,4].
The genomic inflation factors of the individual studies (Table S1)
and overall meta-analysis (lgc = 1.02) were low, indicating that the
observed GWA results were not due to population stratification.
The fixed-effect meta-analytic data from all seven cohorts
demonstrated a substantial excess of significant associations with
AGA at the tail of the QQ plot (Figure S1). We identified a total of
645 SNPs that achieved genome-wide significance (p,561028,
Table 2, Table S2). The fixed-effect meta-analytic results showed
no evidence of substantial heterogeneity across populations (Tables
S1 and S2).
Consistent with our previous reports [3,4], a susceptibility locus
for AGA on chromosome 20p11 was confirmed over a ,253 kb
interval with the strongest signal arising at rs6047844
(p = 1.71610239, odds ratio (OR)= 1.60, 95% confidence interval
(CI) = 1.49–1.72) (Figure 1). We also showed confirmed association
with AGA at AR gene by highly significant signal spanning the
gene region (OR=2.20, 95% CI= 2.04–2.37, p = 2.40610291 for
risk allele T of top SNP rs2497938). Even after removing SNPs in
these two established AGA loci, the QQ-plot demonstrated an
excess of SNPs associated with AGA (Figure S2).
FOXA2 (forkhead box A2) is worth noting among the flanking
genes at the chromosome 20 locus. Foxa2, the transcription factor
encoded by FOXA2 in mouse, interacts with AR, especially
through DNA binding domain, to regulate gene expression [19]. It
is expressed in prostate tissue and plays a pivotal role in
neuroendocrine prostate tumors, a form of metastatic prostate
tumors, by inducing development from androgen-dependent
tumors to androgen-independent tumors [20–22]. Its expression
was associated with the invasive phenotype in the primary prostate
cancer [22]. Furthermore, the association of metastatic prostate
Author Summary
While most genome-wide association studies (GWAS)
focus on the identification of susceptibility loci for a
specific disease, this hypothesis-free approach also enables
the identification of unexpected associations between
different diseases by taking advantage of the previously
published GWAS associations. Androgenetic Alopecia
(AGA, also known as male pattern baldness) is the most
common type of hair loss in humans. Parkinson’s disease is
reported to occur more commonly in men than in women;
however, there are no studies investigating the link
between AGA and Parkinson’s disease. Here, we show
that a specific genetic locus, chromosome 17q21.31, which
is associated with Parkinson’s disease, is also a suscepti-
bility locus for early-onset AGA. We further investigate the
association between early-onset AGA and Parkinson’s
disease, irrespective of genotype, directly in a large-scale
web-based study. We find that men with early-onset AGA
have 28% higher risk of developing Parkinson’s disease.
The early-onset AGA locus on chromosome 17q21.31 has
also been linked to decreased fertility previously. Future
studies of this locus may implicate novel biological
pathways affecting these three conditions.
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cancer and AGA through AR polymorphisms was previously
described in a well-defined case-control study [14].
Multiple SNPs in strong linkage disequilibrium (LD) (r2.0?6)
revealed a newly discovered association interval encompassing
several genes on chromosome 17q21.31. The most significant signal
of this region was detected for the synonymous (His649His) SNP
rs12373124 (P=5.07610210, OR=1.33, 95%CI=1.21–1.45 for
risk allele T) at the gene IMP5 (intramembrane protease 5). However,
as the genome-wide significant SNPs are highly-correlated with each
other in this region, the most proximal gene is not necessarily the
gene functionally affected by causal SNPs. TheMAPT (microtubule-
associated protein tau) gene, which encodes the tau protein, is of
particular interest in this region because its expression was detected in
hair follicles (p= 9.2261023) but not in the other tissues examined in
our tissue expression analysis (Table S3).
The SNP with the smallest p value, apart from the AGA locus
on chromosome 20, (rs9287638 [A]: OR=1.31, 95% CI= 1.21–
1.41, P=1.01610212), is located on chromosome 2q37, with
seven other genome-wide significant SNPs in the same region.
These SNPs lie 558 kb downstream of HDAC4 (histone deacetylase
4). The next locus mapped within HDAC9 (histone deacetylase 9)
on chromosome 7p21.1 (rs2073963 [G]: OR=1.29, 95%
CI= 1.20–1.38, P=1.08610212). Our expression analysis re-
vealed that HDAC9 and HDAC4 were well expressed in hair
follicles (p = 6.5961023 and 2.6461023 respectively), and HDAC9
was not expressed in skin or scalp tissues (Table S3).
Thus, two independent signals arose from HDACs (HDAC4 and
HDAC9) which act as transcriptional corepressors by deacetylating
nucleosomal histones [23]. By interaction with transcription
factors ARR19 and CRIF1, HDAC4 plays a critical role in
inhibition of AR transactivation [24,25] and its accumulation
coincides with loss of androgen sensitivity in prostate cancer [26].
Furthermore, HDAC9 and HDAC4 share conserved residues and
their tissue specific expression pattern overlaps [27]. Very recently,
ZNF652 which has been shown to be involved in transcriptional
repression effect of HDACs [28] was identified to be a prostate
cancer susceptibility locus [29]. All together, our findings give rise
to the possibility that HDAC4 and HDAC9 might influence
Table 1. Demographic properties of the study subjects in participant studies.
Study Country of origin Descent Study type Sample size
Bonn Germany Germany Case-control (population based) 582 Cases
347 Controls
CoLaus Switzerland European Cohort (community sample) 578 Cases
547 Controls
Iceland Iceland European Cohort (population based) 191 Cases
198 Controls
Nijmegen Netherlands European Cohort (population based) 73 Cases
132 Controls
TwinsUK UK UK Cohort (population based) 162 Cases
210 Controls
23andMe America European Cross-sectional 2,167 Cases
1,753 Controls
Australian Australia European Cohort (population based) 138 Cases
5728 Controls
THISEAS Gr
297 Controls
doi:10.1371/journal.pgen.1002746.t001
Table 2. Summary result for the lead SNP from the genome-wide significant loci.
Genetic Variant Chr. Positiona EAb/NEA EAF OR (95% CI) p value Genec
Number of GW
Significant SNPs I2
rs12565727 1 10955669 A/G 0.789 1.33 (1.22–1.45) 9.07610211 TARDBP 8 ,0.01
rs9287638 2 239359379 A/C 0.562 1.31 (1.21–1.41) 1.01610212 HDAC4 9 0.10
rs2073963 7 18844399 G/T 0.530 1.29 (1.20–1.38) 1.08610212 HDAC9 30 ,0.01
rs6945541 7 68249896 C/T 0.539 1.27 (1.18–1.38) 1.7161029 AUTS2 6 ,0.01
rs12373124 17 41279999 T/C 0.438 1.33 (1.21–1.45) 5.07610210 17q21.31 118 0.24
rs10502861 18 41054146 C/T 0.775 1.28 (1.18–1.39) 2.6261029 SETBP1 16 0.18
rs6047844 20 21985575 T/C 0.460 1.60 (1.49–1.72) 1.71610239 PAX1, FOXA2 277 ,0.01
rs2497938 X 66479743 T/C 0.850 2.20 (2.04–2.37) 2.40610291 AR 181 0.32
Abbreviations: Chr., chromosome; EA, effect allele; NEA, non-effect allele; EAF, effect allele frequency; OR, odds ratio; CI, confidence interval.
a-Chromosome position located in reference sequence of Genome Build 36.3.
b-AGA risk increasing allele on forward strand.
c-Gene harboring the SNP or nearest to the SNP.
See Figure S3 for forest plots of these SNPs. See Table S2 for an expanded version of this table that shows all SNPs with p values less than 561028.
doi:10.1371/journal.pgen.1002746.t002
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European Case-control 219 Caseseece
pathogenesis of AGA through dysregulation of the androgen
pathway, highlighting a shared etiologic factor in this condition
and prostate cancer.
The AUTS2 (autism susceptibility candidate 2) gene was also
identified (lead SNP rs6945541[C]: OR=1.27, 95%CI= 1.18–
1.38, p= 1.7161029) at the chromosome 7q11.22 locus. The
mechanism underlying the association between the AUTS2 locus
and AGA is currently unknown, but its expression profile reveals
abundance of transcript in hair, skin, and scalp (p = 2.6461023,
,1.0061023, and ,1.0061023 respectively, Table S3), but not
blood. Additionally, variants at AUTS2 were recently associated
with the regulation of alcohol consumption through a GWA study
[30]. The function of AUTS2 is currently unknown. It was
previously associated with autism and mental retardation [30].
How the AUTS2 variants affect AGA outcomes deserves further
investigation.
Remaining novel findings include one locus on chromosome 1
which is near the genes TARDBP (TAR DNA binding protein),
PEX14 (peroxisomal biogenesis factor 14), MASP2 (mannan-
binding lectin serine peptidase 2), and SRM (spermidine synthase)
(lowest p= 9.07610211 for SNP rs12565727 [A], OR=1.33,
95%CI= 1.22–1.45) and another locus on chromosome 18q21.1,
near the 39 end of SETBP1 (SET binding protein 1), of which the
most significant was rs10502861 [C] (P=2.6261029, OR=1.28,
95%CI= 1.18–1.39). SETBP1 again demonstrated expression in
hair, skin, and scalp (detection p values are 2.6461023,
,1.0061023, and ,1.0061023 respectively, Table S3), but not
blood.
Regional association plots for seven loci associated with AGA
are shown in Figure 1. Forest plots of the top SNPs are shown in
Figure S3. All these loci were associated with AGA in random-
effect results except the locus on chromosome 18 (Table S4).
While any of the above susceptibility loci may impart a small
risk, examining the combined effect of these loci in individuals
harboring more than one risk allele may improve the ability to
identify individuals at high risk of AGA. Using the top SNPs
identified in this study from both the 6 novel loci and the 2
confirmed regions on chromosome 20p11 and AR gene, we
constructed a genotype risk score based on the weighted number
of susceptibility alleles in an independent replication sample from
23andMe study. As shown in Table 3, there was an increased risk
for AGA across each quartile of the genotypic risk score. For the
individuals with a genotype score in the highest quartile, we
observed substantially increased odds for AGA (OR=5.78, 95%
CI= 4.86–6.87, p = 1.4610288), compared to individuals at the
lowest quartile.
Reasoning that AR gene is replicated as the most substantial
genetic component of AGA, we explored the relationship between
AR gene and other AGA susceptibility loci by several complimen-
tary approaches. First, we examined the effect of AR gene on other
Figure 1. Genome-wide meta-analysis results for AGA in MAAN. (A) Manhattan plot showing the 2log10 p value of SNPs against their
chromosomal positions. The genome-wide significant SNPs are green (p value,561028). The points with p value ,1610240 were truncated; the
smallest p value was 2.4610291 at AR gene. (B–I) Regional association plots for eight loci associated with AGA. In each panel, the lead SNP is denoted
in purple with its rs ID and association p value. The color of other SNPs indicates the LD with the lead SNP as red (0.8#r2#1), orange (0.6#r2,0.8),
green (0.4#r2,0.6), light blue (0.2#r2,0.4), and dark blue (r2,0.2). Estimated recombination rates are in light blue.
doi:10.1371/journal.pgen.1002746.g001
Association of AGA and Common Diseases
PLoS Genetics | www.plosgenetics.org 4 May 2012 | Volume 8 | Issue 5 | e1002746
AGA loci by adding an interaction term in the logistic regression
model. We found no evidence for interaction (Table S5), which is
consistent with our previous reports [4,31]. Second, we sought
clues of interaction between AR gene and other AGA loci
mediated by AR binding sites since AR functions as a transcription
factor. Although a large number of genes were found to be targets
of AR, no AR binding sites have been identified in any of the
candidate genes at AGA loci [32,33]. However, as aforemen-
tioned, among these candidate genes, interaction with AR and
consequent regulation on an epididymis-specific gene has been
shown on FOXA2 (chromosome 20 locus), and the candidate gene
at chromosome 2 locus, HDAC4, was reported to act as an
inhibitor of AR, especially in prostate cancer cells, suggesting that
these two loci may have a role in androgen-dependent pathway.
We identified that the 17q21.31 locus overlaps with a widely
replicated locus that is strongly associated with Parkinson’s disease
[34–38]. Interestingly, MAPT on this locus contained identical
genome-wide significant risk alleles that were shared between
AGA (rs2942168 [G], [OR=1.25, 95% CI= 1.15–1.36,
p = 1.9561027]) and Parkinson’s disease (OR=1.32,
95%CI= 1.23–1.39, p = 1.62610218) reported in a recently
published large GWA study [38]. The lead AGA SNP
(rs12373124) at the 17q21.31 locus is in high linkage disequilib-
rium (r2=0?87) with SNPs that have been associated with
Parkinson’s disease in recent GWA studies [34,35].
To explore this unexpected relationship between Parkinson’s
disease and early-onset AGA we next sought to understand
whether AGA itself was a risk factor for Parkinson’s disease. From
among a superset of the early-onset AGA cases and controls using
the same definition for AGA as in the meta-analysis, we identified
568 self-reported physician diagnosed Parkinson’s disease cases,
and 7,664 population controls [39]. This definition of Parkinson’s
disease has been used previously to replicate genetic loci for this
condition in the 23andMe cohort [39]. We found that AGA cases
had significantly higher odds of Parkinson’s disease (OR=1.28,
95% CI=1.06–1.55, p = 8.961023). Restricting the analysis to
714 individuals with current age 70 or higher, the association was
stronger (OR=1.94, 95% CI= 1.31–2.88, p= 6.561024).
To investigate whether the shared genetic association at
17q21.31 explained the association between Parkinson’s disease
and AGA, we evaluated a regression model with an additional
term for an individual’s genotype at rs12185268, which is the
variant in this region most strongly associated with Parkinson’s
disease in the 23andMe study. The OR for association with early-
onset AGA and its significance were essentially unchanged
(OR=1.96, 95% CI=1.32–2.90, p = 6.061024). In the individ-
uals in the age 70 or higher group, we also tested the association
between Parkinson’s disease and AGA stratified by rs12185268
genotypes. The AG and GG genotypes are pooled due to the small
proportion of GG homozygotes. There is no essential difference
between the odds ratios for individuals with rs12185268 AA
genotypes (OR=1.93, 95% CI= 1.16–3.21, p = 8.761023) and
AG+GG genotypes (OR=2.07, 95% CI= 1.09–3.93,
p = 2.261022), indicating that rs12185268 does not modify the
association between Parkinson’s disease and early-onset AGA.
We next looked for evidence that any other loci associated with
Parkinson’s disease were also associated with early-onset AGA, or
vice versa. We identified the lead SNPs from 27 loci with
p,1.061025 for association with AGA, and 31 loci with
p,1.061025 for association with Parkinson’s disease. We tested
the AGA loci for association with Parkinson’s disease, and the
Parkinson’s disease loci for association with AGA. The 17q21.31
locus was the only locus demonstrating convincing evidence for
association across both phenotypes (Tables S6 and S7).
Parkinson’s disease is the second most common neurodegener-
ative disorder with a prevalence of one percent in individuals that
are over 60 years old [40]. Despite the often-reported higher
prevalence of Parkinson’s disease in men, as compared to women
[40], there are no previous reports investigating the relationship
between AGA and Parkinson’s disease. This novel association
between Parkinson’s disease and early-onset AGA indicated that
there could be a shared genetic or environmental cause for both
conditions.
Our data specifically identify genetic variation in the 17q21.31
region as shared genetic risk factors for these two conditions. To
date, only drug-induced hair loss has been described in patients
having Parkinson’s disease after use of dopamine agonist [41],
although most of the patients affected by drug-induced hair loss
are females [41]. As noted above, a greater incidence of
Parkinson’s disease has been reported in elderly men than in
women [40] and androgen mediated neurotoxicity has been
proposed to contribute to the gender bias in Parkinson’s disease
[42]. Since this association is entirely novel, it is unlikely that our
results have arisen due to recall bias. In addition, the AGA cases in
23andMe study had an age of onset less than 40 years old. The
mean age at diagnosis of Parkinson’s disease is 70.5 years [43].
Therefore it is highly unlikely that Parkinson’s disease occurred
before AGA, as defined in the 23andMe study. At present we are
unaware of any prospective Parkinson’s disease cohorts having
collected AGA data to further explore this relationship, and our
evidence provides rationale to undertake such studies.
Furthermore, the 17q21.31 locus harbors an inversion poly-
morphism that has previously been described to be under negative
selection pressure and has been demonstrated to be associated
with decreased fertility in women [44]. We found a genome-wide
significant SNP for early-onset AGA, whose risk allele (rs1800547
[A], p = 2.8561028, OR=1.27, 95%CI= 1.16–1.39) represents
the H1 haplotype of the 17q21.31 inversion. This H1 haplotype is
under negative selection pressure in Europeans [45] and Icelandic
female carriers of the H1 lineage have fewer children than non-
Table 3. Genotype score associated with the risk of androgenetic alopecia.
Genotype scorea OR (95% CI) p value p value for Trend across all 4 quartiles
Quartile 1 1.00 (Reference)
Quartile 2 2.20 (1.87–2.59) 6.1610221
Quartile 3 3.50 (2.96–4.13) 1.8610249
Quartile 4 5.78 (4.86–6.87) 1.4610288 2.36102101
Abbreviations: OR, odds ratio; CI, confidence interval.
a-The top SNPs from each genome-wide significant loci as shown in Table 2 are used in risk score analysis.
doi:10.1371/journal.pgen.1002746.t003
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carriers, while men sharing this haplotype have a trend towards
decreased fertility [44]. We note that previous studies have
identified an association between polycystic ovarian syndrome
(PCOS), which is the most common cause of anovulatory infertility
in women [46], and early-onset AGA in their male relatives
[47,48]. And increased androgen levels strongly affect both traits.
Our findings, therefore, provide rationale to explore the androgen
pathway as a possible explanation for the decreased fertility
associated with the H1 haplotype in women.
Even though the definition of hair loss and the method of
sampling differed between the eight study groups, the associations
of five genome-wide significant loci were essentially identical in
fixed- and random-effects analysis, suggesting that our results are
unlikely to be influenced by heterogeneity.
We are aware that some other diseases, including progressive
supranuclear palsy, corticobasal degeneration, frontotemporal
dementia and Pick disease are also strongly associated with
17q21.31 region [49,50]. However it is difficult to test the
association between these diseases and AGA. In this study, we
focused on the early-onset AGA. The AGA cases we recruited are
young. In addition, due to the low prevalence (between 6.4 and 15
per 100,000 [51–53]) of these diseases compared to Parkinson’s
disease, we do not have samples to test the association.
Since 17q21.31 locus has been recognized as a risk factor for
Parkinson’s disease, it is plausible that an individual’s status of
Parkinson’s disease may have an effect on the association between
17q21.31 locus and early-onset AGA. We undertook an associa-
tion analysis conditioned on Parkinson’s disease in 8,232
individuals for whom both phenotype are available and confirmed
that status of Parkinson’s disease does not affect the strength of
association between AGA and rs12185268, the top variant at
17q21.31 locus in this sample (unconditioned: OR=0.76, 95%
CI= 0.70–0.82, p = 7.9610213; conditioned: OR=0.76, 95%
CI= 0.70–0.82, p = 7.9610213). This result was verified within
strata of Parkinson’s disease: OR is 0.69 in the cases (95%
CI= 0.51–0.94, p = 1.861022) and 0.76 for individuals without
Parkinson’s disease (95% CI= 0.71–0.83, p = 1.1610211). Further,
the relationship between the 17q21.31 locus and Parkinson’s
disease was not affected by conditioning on AGA status although
the association with rs12185268 was not significant (uncondi-
tioned: OR=0.99, 95% CI= 0.84–1.15, p = 0.86; conditioned:
OR=1.00, 95% CI= 0.86–1.17, p= 0.97).
Our data demonstrated several aspects of the relationship
between AGA and Parkinson’s disease: First, variants at 17q21.31
locus including the MAPT gene are associated with both risk of
Parkinson’s disease (p = 2.8610212) and early onset AGA
(p= 9.361028) as shown in Table S6 and S7. Second, early onset
AGA (age of onset ,40 years), is a risk factor for Parkinson’s
disease (p = 8.961023). Third, controlling for variation at
rs12185268, the top SNP at 17q21.31 locus, does not eliminate
the relationship between AGA and Parkinson’s disease. And
fourth, the other genetic determinants of AGA, as described
through GWAS, do not influence risk of Parkinson’s disease and
vice versa. Given that the 17q21.31 locus does not fully explain the
association between AGA and Parkinson’s disease, and that we do
not see more broad overlap between susceptibility loci for AGA
and Parkinson’s disease, it could be that the association between
these phenotypes is mediated by an unobserved, shared environ-
mental or genetic risk factor.
The identification of the new associations in this report was
driven primarily by augmented power arising from the expanded
sample size, which was more than fourfold that of previous GWA
analyses [3,4]. Similar to previous GWA studies [54], this increase
in power was associated with a decrease in effect sizes from newly
identified loci (top ORs range from 1?27 to 1?33 for six new loci
versus OR=1?60 for the lead SNP on chromosome 20). In this
regard, it seems likely that more variants with smaller effect sizes
could be uncovered by future larger studies to full describe the
allelic architecture of early-onset AGA.
In conclusion, our findings provide fresh insights into the
pathogenesis of early-onset AGA. As these newly identified
susceptibility loci are also implicated in Parkinson’s disease,
prostate cancer and fertility, our results highlight the importance
of hypothesis-free genetic studies, which allow unexpected genetic
relationships between conditions to uncover shared etiologies.
Materials and Methods
Ethics Statement
All seven studies were approved by institutional ethics review
committees at the relevant organizations, and written informed
consent was provided by all participating individuals.
Study Participants
All the participants for this genome-wide meta-analysis were
drawn from seven studies: Bonn (582 cases and 347 controls),
CoLasu (578 cases and 547 controls), TwinsUK cohort (162 cases
and 210 controls), Nigmegen Biomedical Study (73 cases and 132
controls), 23andMe (2,167 cases and 1,753 controls), Iceland (191
cases and 198 controls), Australian population based twin study
(138 unrelated cases and 5728 unrelated controls). A detailed
description of all these studies and phenotype definitions used in
current study is provided in Text S1.
Genotyping and Quality Controls
The genotyping platforms, imputation methods and genome
wide association methods used in participant studies are provided
in Table S1. Extensive quality control thresholds were applied to
include common SNPs (minor allele frequency $1%) with a high
call rate ($95%) for genotyped SNPs, and imputed SNPs with
high quality metrics (variance ratio $0.3 for MACH and proper
info statistic $0.4 for IMPUTE) [55,56]. In addition, SNPs
demonstrating deviation from Hardy Weinberg Equilibrium
(p.1026) were excluded. The test statistics for each cohort at
each SNP were corrected for their respective genomic inflation
factors to avoid inflation of results due to population stratification.
Meta-Analysis
We carried out a meta-analysis under both fixed- and random-
effects models using the inverse-variance method to combine
results from each study using an additive genetic model, while
correcting for the genomic inflation factor for each study and the
overall meta-analysis. To implement this strategy GWAMA
software was used for SNPs on autosomes [57]. Based on the
data available, association results using pre-imputation SNPs from
Bonn, CoLaus, TwinsUK cohort, Nigmegen Biomedical Study,
23andMe and Australian population based twin study were used
for meta-analysis on X chromosome through YAMAS program
(http://yamas.meb.uni-bonn.de/index.html). Proxy association
was applied to gain a higher power. We also tested for evidence
of heterogeneity of effects between SNPs and AGA across studies
using the Cochran’s Q statistics and I2 measurement. SNPs with
low heterogeneity (Q p value.0?10 and I2,50%) and present in at
least three individual studies are reported. In order to test for an
inflation of test statistics and the presence of a signal arising from
the data for the variants influencing AGA, we constructed
quantile-quantile (QQ) plots [58]. Genome-wide significance was
set at a p value of 561028 [59].
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Genome-wide suggestive SNPs (561028,p,561026, n = 397)
that were imputable using the MetaboChip platform were
followed-up in an expanded meta-analysis including the THI-
SEAS study [60] (Text S1, 297 controls and 219 cases) and the
original seven cohorts. This additional cohort joined the consor-
tium after completion of the main meta-analysis. No additional
loci achieved genome-wide significance after inclusion of this
cohort.
Expression Methods
To understand whether the identified SNPs are in close
proximity to genes that show differential expression in hair
follicles, we performed tissue expression analysis. In brief, total
RNA extracted from human hair follicles, skin from temple, scalp,
and whole blood were used for array-based gene expression
analysis. The differential expression of genes in these tissues was
determined by the average signal of identical probes and detection
p values (which is significant, if a gene is reliably expressed).
Further details are provided in Text S1.
Genotype Risk Score
In genotype risk score analysis, the association between a
genotype risk score based on the weighted number of susceptibility
alleles and AGA status was determined. Six novel susceptibility
loci, chromosome 20p11 locus and AR gene are included. The
weights were established using b coefficients for AGA susceptibility
from meta-analysis. The resultant genotypic risk score was divided
into quartiles and the risk of AGA for each quartile was tested in
an additional set of subjects in 23andMe study, which were not
included in the original meta-analysis, using the lowest risk
quartile as the reference group. We identified 1582 controls and
1765 cases for this analysis, using the same phenotypic definition
used in the meta-analysis. The genotype data is complete without
missing values based on phasing and imputation. The trend for
risk across the quartiles was tested using the non-parametric trend
test [61].
Interaction Analysis
To detect the potential modification effect of AR gene on any
other AGA loci, an interaction analysis was deployed using top
SNPs identified from meta-analysis. Each SNP was coded by the
number of AGA risk-increasing allele. The test of interaction is
based on the coefficient b3 of the interaction term in the logistic
regression model Y= b0+b1 * A+b2 * B+b3 * AB+e. The
Bonferroni correction was applied to address the multiple
comparisons problem and the significance level was set to p
value,761023.
Association with Other Common Diseases
In order to better understand whether the identified risk loci
from the meta-analysis were associated with common diseases, we
searched the AGA susceptibility loci using the GWAS Integrator
embedded in HuGE Navigator website [62]. This online reference
tool collects data from all published genetic studies in humans to
facilitate the identification of shared etiologic pathways between
diseases. Due to the frequent publication of new GWAS, only the
GWAS searched out before June 2011 were used.
To examine the relationship between Parkinson’s disease and
AGA, we performed a logistic regression of Parkinson’s disease
status against AGA status, evaluating significance of the AGA term
by analysis of deviance using a likelihood ratio test. To control for
confounding factors, we included age, age2, and the top five
principal components derived from genotype data as covariates.
Supporting Information
Figure S1 Quantile–quantile plot of Meta-Analytic Results.
(Genomic Control was applied to each individual cohort prior to
meta-analysis and the overall results).
(TIF)
Figure S2 Quantile–quantile plot of Meta-Analytic Results after
removing SNPs of AGA locus on chromosome 20 and SNPs of AR
locus on chromosome X. (Genomic Control was applied to each
individual cohort prior to meta-analysis and the overall results).
(TIF)
Figure S3 Forest Plots of the Lead SNP from Genome-Wide
Significant Loci.
(TIF)
Table S1 Genotyping, imputation and statistical analysis used in
the GWA studies.
(DOCX)
Table S2 Genome-Wide Significant SNPs in fixed-effect model
(p,561028).
(DOC)
Table S3 Average Expression Signal for All Genes Shown in
Figure 1 across Three Tissue Types and Blood.
(DOC)
Table S4 Summary result for the top SNPs from the genome-
wide significant loci using random effect models.
(DOC)
Table S5 Interaction results between top SNPs of AR locus and
other AGA loci.
(DOC)
Table S6 Association test results for AGA, at Parkinson’s disease
loci.
(DOC)
Table S7 Association test results for Parkinson’s disease, at AGA
loci.
(DOC)
Text S1 Description of participant studies and phenotype
definition. Methods of tissue expression analysis are also described.
(DOC)
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